EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Personalised treatment in hpv-positive oropharyngeal squamous cell cancer: Insights from molecular biology to clinical trials

Kumar Masum iD, Balakeshwa Ramaiah iD

Journal of Oncology Pharmacy Practice · 25.05.2026

DOI: 10.1177/10781552261455296 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 25.05.2026. Verfasst von Kumar Masum und 1 weiteren Autor:innen. Beteiligte Einrichtung: Doctor of Pharmacy, Department of Pharmacy Practice, Bangalore Baptist Hospital, Bengaluru, India. Die Arbeit nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review current evidence on the epidemiology, molecular biology, and evolving treatment strategies of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), with particular emphasis on treatment de-escalation and personalized therapeutic approaches. Data Sources A systematic literature search was performed using PubMed/MEDLINE, Scopus, Web of Science, Embase, and ClinicalTrials.gov. Studies published between January 2000 and March 2026 were identified using keywords related to HPV-positive OPSCC, tumor biology, treatment de-escalation, immunotherapy, and circulating tumor HPV DNA. Of 145 records retrieved, 25 duplicates were removed and 120 studies were screened. Following full-text assessment, 67 HPV-positive OPSCC–related studies were included in the final qualitative synthesis. Data Summary HPV-positive OPSCC has emerged as a distinct clinical and biological entity with rapidly increasing incidence, particularly in high-income regions. Compared with tobacco-associated head and neck cancers, HPV-positive disease affects younger individuals and demonstrates improved treatment responsiveness and survival outcomes. Viral oncoproteins disrupt cell-cycle regulation, immune surveillance, and genomic stability, driving tumor development. Despite favorable survival, long-term treatment-related morbidity remains significant. Consequently, numerous clinical trials are evaluating treatment de-escalation strategies, including reduced-dose radiotherapy, modified systemic therapy, and surgery-based approaches in selected patients.

Conclusions

Advances in molecular understanding and biomarker-driven approaches are shaping personalized management strategies for HPV-positive OPSCC. Carefully designed clinical trials and improved patient selection are essential to optimize oncologic outcomes while minimizing treatment-related toxicity.

Schlagwörter

Stichwörter der Autor:innen

HPV-positive oropharyngeal cancerbiomarker-guided therapycirculating tumortreatment de-escalation

Autor:innen und Institutionen

  • Doctor of Pharmacy, Department of Pharmacy Practice, Bangalore Baptist Hospital, Bengaluru, India.
  • Head of department, Department of Pharmacy Practice, Karnataka college of pharmacy, Bengaluru, India.

ORCID-Profile: Kumar Masum, Balakeshwa Ramaiah

Zitieren

APA

Masum, K., & Ramaiah, B. (2026). Personalised treatment in hpv-positive oropharyngeal squamous cell cancer: Insights from molecular biology to clinical trials. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552261455296

Vancouver

Masum K, Ramaiah B. Personalised treatment in hpv-positive oropharyngeal squamous cell cancer: Insights from molecular biology to clinical trials. Journal of Oncology Pharmacy Practice. 2026. doi:10.1177/10781552261455296

BibTeX
@article{Masum2026,
  author = {Masum, Kumar and Ramaiah, Balakeshwa},
  title = {Personalised treatment in hpv-positive oropharyngeal squamous cell cancer: Insights from molecular biology to clinical trials},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2026},
  doi = {10.1177/10781552261455296}
}
Kostenlos starten →